Last reviewed · How we verify

Maintenance of alpha-blocker and 5-ARI

Gangnam Severance Hospital · Phase 3 active Small molecule

Maintenance of alpha-blocker and 5-ARI is a Alpha-blocker and 5-alpha reductase inhibitor combination Small molecule drug developed by Gangnam Severance Hospital. It is currently in Phase 3 development for Benign prostatic hyperplasia with lower urinary tract symptoms.

This combination therapy maintains symptom relief in benign prostatic hyperplasia by combining alpha-blocker-mediated smooth muscle relaxation with 5-alpha reductase inhibitor-mediated reduction of prostate volume.

This combination therapy maintains symptom relief in benign prostatic hyperplasia by combining alpha-blocker-mediated smooth muscle relaxation with 5-alpha reductase inhibitor-mediated reduction of prostate volume. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.

At a glance

Generic nameMaintenance of alpha-blocker and 5-ARI
SponsorGangnam Severance Hospital
Drug classAlpha-blocker and 5-alpha reductase inhibitor combination
TargetAlpha-1 adrenergic receptor and 5-alpha reductase enzyme
ModalitySmall molecule
Therapeutic areaUrology
PhasePhase 3

Mechanism of action

Alpha-blockers relax smooth muscle in the prostate and bladder neck to improve urinary flow and reduce lower urinary tract symptoms. 5-alpha reductase inhibitors (5-ARI) block conversion of testosterone to dihydrotestosterone, reducing prostate size over time. Together, they address both acute symptom relief and long-term disease progression in benign prostatic hyperplasia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Maintenance of alpha-blocker and 5-ARI

What is Maintenance of alpha-blocker and 5-ARI?

Maintenance of alpha-blocker and 5-ARI is a Alpha-blocker and 5-alpha reductase inhibitor combination drug developed by Gangnam Severance Hospital, indicated for Benign prostatic hyperplasia with lower urinary tract symptoms.

How does Maintenance of alpha-blocker and 5-ARI work?

This combination therapy maintains symptom relief in benign prostatic hyperplasia by combining alpha-blocker-mediated smooth muscle relaxation with 5-alpha reductase inhibitor-mediated reduction of prostate volume.

What is Maintenance of alpha-blocker and 5-ARI used for?

Maintenance of alpha-blocker and 5-ARI is indicated for Benign prostatic hyperplasia with lower urinary tract symptoms.

Who makes Maintenance of alpha-blocker and 5-ARI?

Maintenance of alpha-blocker and 5-ARI is developed by Gangnam Severance Hospital (see full Gangnam Severance Hospital pipeline at /company/gangnam-severance-hospital).

What drug class is Maintenance of alpha-blocker and 5-ARI in?

Maintenance of alpha-blocker and 5-ARI belongs to the Alpha-blocker and 5-alpha reductase inhibitor combination class. See all Alpha-blocker and 5-alpha reductase inhibitor combination drugs at /class/alpha-blocker-and-5-alpha-reductase-inhibitor-combination.

What development phase is Maintenance of alpha-blocker and 5-ARI in?

Maintenance of alpha-blocker and 5-ARI is in Phase 3.

What are the side effects of Maintenance of alpha-blocker and 5-ARI?

Common side effects of Maintenance of alpha-blocker and 5-ARI include Erectile dysfunction, Decreased libido, Dizziness, Retrograde ejaculation, Orthostatic hypotension.

What does Maintenance of alpha-blocker and 5-ARI target?

Maintenance of alpha-blocker and 5-ARI targets Alpha-1 adrenergic receptor and 5-alpha reductase enzyme and is a Alpha-blocker and 5-alpha reductase inhibitor combination.

Related